BackGuobang Pharma Overview

Guobang Pharma EBIT

Track Guobang Pharma's EBIT ($750M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$157.52M
↓ 39.54% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$749.80M
↓ 16.72% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Guobang Pharma (605507.SS) FAQ

The latest EBIT for 605507.SS is $750M as of September 2026. That compares with $900M in the prior-year period — down 16.7% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Guobang Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, 605507.SS's EBIT moved from $900M to $750M — a 16.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Guobang Pharma's operating scale or balance-sheet position.

Against its sector companies, 605507.SS currently prints $750M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Guobang Pharma's growth, margins, and balance sheet.

A EBIT figure of $750M for 605507.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting 605507.SS's EBIT ($750M), review year-over-year change from $900M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.